Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses

Gene Therapy

Volumn 17, Issue 5, 2010, Pages 634-642

  Sharma, A ^a,b   Tandon, M ^a,b   Ahi, Y S ^a,b   Bangari, D S ^a,c   Vemulapalli, R ^a   Mittal, S K ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

Cell mediated immunity; Nonhuman adenoviral vectors; Preexisting vector immunity

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; BOVINE ADENOVIRUS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN ADENOVIRUS; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PORCINE ADENOVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; VIRUS NEUTRALIZATION; VIRUS TITRATION; WILD TYPE;

ADENOVIRUSES, HUMAN; ADENOVIRUSES, PORCINE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CATTLE; CROSS REACTIONS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS;

BOVINAE; BOVINE ADENOVIRUS 3; MUS; PORCINE ADENOVIRUS; PORCINE ADENOVIRUS 3;

EID: 77952428444     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.1     Document Type: Article

References (46)

1. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 2004; 6: 597-602.
2. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adeno-viruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
3. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
4. Moffatt S, Hays J, HogenEsch H, Mittal SK. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 2000; 272: 159-167.
5. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, Piedra PA et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999; 96: 12816-12821.
6. Mastrangeli A, Harvey BG, Yao J, Wolff G, Kovesdi I, Crystal RG et al. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
7. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 2006; 24: 849-862.
8. Stone D, Lieber A. New serotypes of adenoviral vectors. Curr Opin Mol Ther 2006; 8: 423-431.
9. Wold WS, Horwitz MS. Adenoviruses. In: Knipe DM and Howley PM (ed). Fields Virology. Walters Kluwer Health-Lippincott Williams & Wilkins: Philadelphia, 2007, pp 2395-2436.
10. Bauer U, Flunker G, Bruss K, Kallwellis K, Liebermann H, Luettich T et al. Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. J Clin Microbiol 2005; 43: 4426-4433.
11. Bakay M, Szalay K, Beladi I, Balint E, Lengyel A, Adam E et al. Cross-reactivity between human adenoviruses in delayed-type hypersensitivity. APMIS 2005; 113: 197-202.
12. Heemskerk B, Veltrop-Duits LA, van VT, ten Dam MM, Heidt S, Toes RE et al. Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. J Virol 2003; 77: 6562-6566.
13. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther 1998; 9: 1419-1427.
14. Olive M, Eisenlohr LC, Flomenberg P. Quantitative analysis of adenovirus-specific CD4+ T-cell responses from healthy adults. Viral Immunol 2001; 14: 403-413.
15. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Characterization of human proliferative T cell responses to adenovirus. J Infect Dis 1995; 171: 1090-1096.
16. Flomenberg P, Piaskowski V, Truitt RL, Casper JT. Human adenovirus-specific CD8+ T-cell responses are not inhibited by E3-19 K in the presence of gamma interferon. J Virol 1996; 70: 6314-6322.
17. Bangari DS, Shukla S, Mittal SK. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 2005; 327: 960-966.
18. Li X, Bangari DS, Sharma A, Mittal SK. Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology 2009; 392: 162-168.
19. Bangari DS, Mittal SK. Porcine adenovirus serotype 3 inter-nalization is independent of CAR and alpha(v)beta(3) or alpha(v)beta(5) integrin. Virology 2005; 332: 157-166.
20. Bangari DS, Sharma A, Mittal SK. Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun 2005; 331: 1478-1484.
21. Sharma A, Bangari DS, Tandon M, Pandey A, HogenEsch H, Mittal SK. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 2009; 386: 44-54.
22. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 2008; 16: 965-971.
23. Doherty PC, Turner SJ. Memories of virus-specific CD8+ T cells. Immunol Cell Biol 2004; 82: 136-140.
24. Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, Drinker M et al. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. J Virol 2009; 83: 5567-5573.
25. Perreau M, Kremer EJ. The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy. Mol Biotechnol 2006; 34: 247-256.
26. Jooss K, Ertl HC, Wilson JM. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol 1998; 72: 2945-2954.
27. Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, Gahery-Segard H et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 2002; 76: 127-135.
28. Rawle FC, Knowles BB, Ricciardi RP, Brahmacheri V, Duerksen-Hughes P, Wold WS et al. Specificity of the mouse cytotoxic T lymphocyte response to adenovirus 5. E1A is immunodominant in H-2b, but not in H-2d or H-2k mice. J Immunol 1991; 146: 3977-3984.
29. McKelvey T, Tang A, Bett AJ, Casimiro DR, Chastain M. T-cell response to adenovirus hexon and DNA-binding protein in mice. Gene Ther 2004; 11: 791-796.
30. Olive M, Eisenlohr L, Flomenberg N, Hsu S, Flomenberg P. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. Hum Gene Ther 2002; 13: 1167-1178.
31. Rux JJ, Kuser PR, Burnett RM. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution X-ray crystallographic, molecular modeling, and sequence-based methods. J Virol 2003; 77: 9553-9566.
32. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-1583.
33. Perreau M, Kremer EJ. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 2005; 79: 14595-14605.
34. Duncan SJ, Gordon FC, Gregory DW, McPhie JL, Postlethwaite R, White R et al. Infection of mouse liver by human adenovirus type 5. J Gen Virol 1978; 40: 45-61.
35. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adeno-virus vectors. Nat Med 1996; 2: 545-550.
36. Yang Y, Haecker SE, Su Q, Wilson JM. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 1996; 5: 1703-1712.
37. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther 1996; 3: 137-144.
38. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS et al. Decreased tumorigenic potential of EphA2-over-expressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 2004; 11: 757-766.
39. Bangari DS, Mittal SK. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Viru s R es 2004; 105: 127-136.
40. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977; 36: 59-74.
41. van Olphen AL, Tikoo SK, Mittal SK. Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology 2002; 295: 108-118.
42. van Olphen AL, Mittal SK. Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted. J Virol 2002; 76: 5882-5892.
43. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172: 6290-6297.
44. Vogels R, Zuijdgeest D, van RR, Hartkoorn E, Damen I, de Bethune MP et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-8271.
45. Parish CR, Mullbacher A. Automated colorimetric assay for T cell cytotoxicity. J Immunol Methods 1983; 58: 225-237.
46. Sambhara S, Switzer I, Kurichh A, Miranda R, Urbanczyk L, James O et al. Enhanced antibody and cytokine responses to influenza viral antigens in perforin-deficient mice. Cell Immunol 1998; 187: 13-18.